Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Discovery may help to fight ovarian cancer
http://www.heraldtribune.com/business/d-index.cfm
Focused Plenary Session on Ovarian Cancer
http://www.sgo.org/meetings/33annual/abstracts/abstract.asp?abstractid=21
Determination of a Candidate Gene in Predicting In-Vivo Ovarian Cancer Response to Combination Therapy with Carboplatin and Paclitaxel
Ramin Mirhashemi*, J Fernando Arena, Tony Frudakis, Nicholas Lambrou, Jane Arboleda, Marsha Hunt, Hervy E Averette, Manuel A Penalver. Univ of Miami, Sch of Medicine, Miami, FL, DNAPrint Genomics, Sarrasota, FL.
Objectives: Patient response rates to primary treatment of ovarian cancer with combination of paclitaxel and the carboplatin agents is subject to a high degree of uncertainty and inter-individual variability. In an attempt to define the genetic determinants for this variability, we are conducting a pharmacogenomics study to predict response based on patient genomics.
Methods: Our approach is a systematic haplotype-based candidate gene approach, where we genotype each patient at each single nucleotide polymorphic (SNP) site for each gene known to be relevant for xenobiotic disposition, then computationally infer haplotypes, and geometrically model the data in order to identify associations between haplotypes and response. We have chosen this novel approach to objectively define an optimal pharmacogenomics solution.
Results: We have constructed SNP maps for 50 genes known to be involved in xenobiotic metabolism and/or the disposition of paclitaxel and carboplatin and have discovered an average of 30 candidate SNPs per gene, which, upon polymorphism screening, validated at a rate of about 18 SNPs per gene. Having obtained genotypes for 57 patients at each of the SNPs in several genes, preliminary results have revealed a statistically significant association (Fishers Exact p=0.00332 ± 0.00043) between haplotypes at the CYP3A4 gene and a lack of response to paclitaxel/carboplatin as measured by the CA-125 tumor marker. In particular, the GAC and GAT CYP3A4 haplotypes were only present in the non-responder group (n=22), when an absolute decrease in CA-125 was used to define responders (n=40). When a 20% decrease in CA-125 was used, a similar result was obtained (Fishers Exact p=0.016 ± 0.001); GAC was found in the non-responder group 71% of the time, and the GAT haplotype was found in the non-responder group 100% of the time.
Conclusions: SNPs in candidate genes being identified could potentially be used pre-treatment to individualize chemotherapy for patients with ovarian cancer. This in vivo assay could help classify ovarian cancer patients as potential responders or non-responders to our conventional chemotherapeutic agents.
Society of Gynecologic Oncologists
401 N. Michigan Avenue
Chicago, IL 60611
(312) 644-6610
E-mail: sgo@sba.com
( BW)(MA-DNAPRINT-GENOMICS)(DNAP) DNAPrint Presents Paclitaxel Response Study Results at BioITWorld Expo; Response to Common Ovarian CancBusiness Editors & Health/Medical Writers
BIOWIRE2K
BioITWorld 2002
BOSTON--(BW HealthWire)--March 14, 2002--DNAPrint genomics, Inc. (OTCBB:DNAP) announced today successful results from an ongoing collaboration with the University of Miami aimed at identifying the genetic basis for variable paclitaxel (Taxol) response in cancer patients. Dr. Tony Frudakis, Chief Executive Officer of DNAPrint genomics presented the results at the BioITWorld Expo in Boston, MA on March 14th.
"We've identified a set of variant human genes that we believe can be used to predict therapeutic outcomes for paclitaxel," said Dr. Tony Frudakis, CEO of DNAPrint genomics. "Given the consequences of inefficacy, it will be of great value to know when treatments based on population means should not be prescribed."
As currently administered, roughly 30% of ovarian cancer patients fail to respond to paclitaxel (Taxol)-based combination treatments during first line chemotherapy. Genetic tests, focused on the part of the genome known to be involved in drug metabolism, were performed on ovarian cancer patients that responded to the treatment and the results compared to those that did not. Haplotype sequences in two genes that are associated with non-response were identified.
Management believes that the results presented at the meeting constitute the core for developing a predictive genetic test called the OVANOME classifier, which could be used to economically evaluate the suitability of cancer patients for standard doses of paclitaxel chemotherapy during first line treatment for ovarian cancer. The test may have implications for enhancing first line chemotherapy success rates for patients with a variety of cancer types.
Doctors from the University of Miami will present the results on March 19th at the 33rd annual meeting of the Society of Gynecologic Oncologists in Miami, FL. For the past year, DNAPrint has been collaborating with the University of Miami Familial Ovarian and Breast Cancer Center in Miami, FL, to identify the complex genetic determinants for variable paclitaxel response in ovarian cancer patients. DNAPrint has already received a grant to extend these results in-vitro, using a model system for paclitaxel response, and is teaming with the University of Miami to fund additional work aimed at validating the value of the test for guiding patient treatment decisions.
About DNAPrint genomics, Inc.
DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical and statistical modeling, programming and molecular genetics. Our quest is to become the leader in the development of complex pharmacogenomics classifiers for a personalization of drug prescription. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit http://www.dnaprint.com.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
--30--pp/mi*
CONTACT: DNAPrint genomics, Inc., Sarasota
Investor Contact: Carrie Castillo, 941/366-3400
ccastillo@dnaprint.com
or
Media Contact: Russell LaMontagne, 212/219-0800
russell@corinthgroup.com
KEYWORD: FLORIDA MASSACHUSETTS
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL PHARMACEUTICAL EDUCATION
TRADESHOW
SOURCE: DNAPrint genomics, Inc.
er Treatment Shows Strong Genetic Basis
DNAPrint Files Patent for Complex Genomics Algorithm
http://www.investors.com/newswire/nwnp01.asp
GenoMed, Inc. Adds Tony Frudakis, Ph.D. to Scientific Advisory Board
http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3Ftextpath%3DCOMTEX%5Cbw%5C2001%5C12%5C07...
DNAPrint Collaborates with NYU School of Medicine
SARASOTA, Fla., Dec 3, 2001 /PRNewswire via COMTEX/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP) announced today that it has entered into a collaboration with the New York University School of Medicine to develop pharmacogenomic classifiers for organ transplant patients.
NYU's Mary Lea Johnson Richards Organ Transplantation Center will provide DNAPrint with informed consent qualified patient specimens and matching clinical data. DNAPrint will genetically screen the specimens for markers and/or marker sets that can be used to distinguish between drug responders and non-responders. To do this, the company will employ proprietary genotyping protocols, data resources (the PHENOME SNP database) and its powerful informatics platform.
The goal of the project is to identify pharmacogenomic classifiers that could be used to match renal transplantation patients with the optimal immunosuppressant for their genetic architecture. The project is expected to take about one year to complete, and the results are expected to extend to patients for a wide range of transplantation procedures.
About NYU's Transplant Program:
The Mary Lea Johnson Richards Organ Transplantation Center is one of the busiest and most successful transplant programs in the United States. The program offers transplantation of the liver, kidney and pancreas and performs about 150 transplants annually. Over 500 liver and 200 kidney transplants have been done since program inception and the programs graft and patient survival rates are consistently among the best in the country.
About DNAPrint genomics, Inc.:
DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical and statistical modeling, programming and molecular genetics. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com.
Investor Relations Inquiries please contact:
Tim Wilkins
941/341-0136
twilkins@tbfcorp.net
Or
Carrie Castillo
ccastillo@dnaprint.com
941/366-3400
For Scientific Inquiries, please call:
Dr. Tony Frudakis
941/366-3400
All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X19415882
SOURCE DNAPrint genomics, Inc.
CONTACT: Investor Relations: Tim Wilkins, +1-941-341-0136,
twilkins@tbfcorp.net, or Carrie Castillo, +1-941-366-3400,
ccastillo@dnaprint.com, or Scientific Inquiries: Dr. Tony Frudakis,
+1-941-366-3400, all for DNAPrint genomics Inc.
URL: http://www.dnaprint.com
http://www.prnewswire.com
Copyright (C) 2001 PR Newswire. All rights reserved.
Thank you sarals
DNA Print brings genetic eye test product to market
http://www.newscoast.com/2biz.cfm?ID=55108
DNAPrint Genomics 'Solves' Human Eye Color and Announces
http://quote.bloomberg.com/fgcgi.cgi?T=marketsquote99_news.ht&s=AO914ixO3RE5BUHJp
You guys should look at the prs released after the conference last October. DNAP will mostly like repeat this pattern again. What we will find out is that the platform is finish and one or two solutions are ready to market in the next year or one year and one-half. DNAP s/p will go up (permanently) when ORCH or others see real value in DNAP products. Question is: what value will be placed on the post conference information Dr. Tony gives this weekend?
Happy trading too!!!
DNAPrint (OTC Bulletin Board: DNAP) to Present at Upcoming Conferences
http://quote.bloomberg.com/fgcgi.cgi?T=marketsquote99_news.ht&s=AO8yMqwz5L0MgTyBS
Cariocca, you said it best. I am lucky to be living in a changing world. One that is full of surprises. I hope DNAP is full of wonderful surprises for us!
Selected papers for further reading about Phenomics:
Alizadeh et. al., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000 403: 503-511.
Schilling, C., Edwards, J., and B. Palsson. Toward metabolic phenomics: Analysis of genomic data using flux balances. Biotechnol. Prog. 1999, 15:288-295.
Strothman, R.C. The coming Kuhnian revolution in biology. Nat. Biotechnol. 1997, 15, 194-200.
Fields, S. The future is function. Nat. Genet. 1997, 15, 325-327.
Hieter, P.; Boguski, M. Functional genomics: It’s all how you read it. Science 1997, 278, 601-602.
Palson, B. O. What lies beyond bioinformatics? Nat. Biotechnol. 1997, 15, 3-4.
Ouzounix, C., Casari, G. Computational comparisons of model genomes. Trends Biotechnol. 1996, 14 (Aug), 280-285.
Bonarius, H.P.J., Schmid, G., Tramper, J. Flux analysis of underdetermined metabolic networks: the quest for the missing constraints. Trends Biotechnol. 1997, 15 (Aug) 308-314.
Plomin, Robert. Genetics and general cognitive ability.Nature 402 (suppl.): C25-C29.
http://www.dnaprint.com./index.cfm?fuseaction=content&id=250
Personalized Medicine and Pharmacogenomics
Doctors and pharmacists have long known that individuals respond differently to the same drug. The reason for this is the underlying genetic variability between individuals. Pharmacogenomics is the study of variable drug response against the backdrop of genetic variability and most properly involves a consideration of complex genetics (a good analogy to this system is the flux-balance model in E. Coli- Schilling et al., 1999). Whereas one person may effectively and safely metabolize a certain drug, another may metabolize the same drug into a dangerous toxin or not metabolize it well at all. By evaluating drug response against genotype, it will be possible to define genetic profiles that are compatible with certain treatment regimens and those which are not. In this way, a patient's response to a drug can be accurately predicted before the drug is prescribed. The idea of using a patient's genotype as a factor in deciding on treatment options is commonly referred to as Personalized Medicine. Though today's drugs are approved and developed based on their performance in a large population of people, medicine of the future will be evaluated and prescribed, tailor made for a particular patient's needs.
Copyright DNAPrint genomics © 2000
900 Cocoanut Ave.
Sarasota, FL 34236
(941) 366-3400
Fax # (941) 952-9770
home / company / medicine / science / services / advantages / technology
programs / investors / properties / careers / founders / order / contact / login
Spell check at bottom of "Text Box!"
"SNIPdoc" SNP discovery system
The Company maintains a cutting edge high throughput polymorphism-screening laboratory and the SNiPdoc(tm) system is the discovery search engine for this facility. SNiPdoc(tm) is a software system that designs vertical re-sequencing projects, aligns raw DNA sequence data from multiple donors, and uses proprietary statistical routines to find reliable discrepancies between these sequences. The data is formatted and deposited into a relational database system."
The software designs the re-sequencing (sequencing the same gene from multiple donors) of experiments starting with raw human genome data files (NCBI Genbank). The software system begins by defining "important" and "unimportant" regions of a human genome DNA sequence file, then designs primers to flank pertinent regions of the file through formatting these primers for easy oligonucleotide ordering from third party vendors. The software achieves in seconds what it previously took a scientist an hour or more to accomplish during the tedious process of experimental design. After primer design and amphfication, the software allows the company to identify reliable SNPs through a process called multiple sequence alignment and discrepancy validation. The output of the program is a list of SNPs in FASTA format for assay design. Our system has allowed us to create some of the most dense and reliable Gene polymorphism maps anywhere. Whereas publicly available SNPs validate as Polymorphisms at a rate of about 50-60%. Our result is greater than 95%.
Copyright DNAPrint genomics © 2000
900 Cocoanut Ave.
Sarasota, FL 34236
(941) 366-3400
Fax # (941) 952-9770
PhenomeTM SNiP databases
We have developed unique and comprehensive SNP databases through the use of proprietary, protocols and data mining techniques. At present, we are sequencing 1,000,000 bases of DNA per week. This rate of sequencing has allowed us to discover about 1 novel, quality validated SNP for every 200 bases of target sequence in the human genome. This rate of discovery is greater than that which others have reported in the scientific literature. In contrast to maps present in public resources, the proprietary SNP maps the company is building span the entire length of each target gene. Relatively few of the SNPs comprising these maps are present in public genome database resources. In addition, analysis conducted to date has validated these SNPs (as real polymorphisms) at a significantly higher rate than those taken or "mined" from public database resources. The Company attributes these desirable outcomes to its implementation of unique vertical re-sequencing protocols and proprietary software platform (the patent pending SNiPdoc(tm) system) for raw SNP discovery.
http://www.dnaprint.com./index.cfm?fuseaction=content&id=27
DNAPrint Inks Deal With Pharsight
http://money2.go.com/News?newsRef=Bizwire/20010824/a2133&ticker=ACEL,ADVR,ALLP,AQSE,DNAP,ENDV,LB...
October is a gloomy month for stocks and probably does not bode well for DNAP
either! September and October of this year would not seem to be months that I,
personally would want to see DNAP released goods news into. The lack of market
momentum would skew any news away from positive territory. I look for any news
regarding DNAP discoveries, as Dr. Tony said, to be given to us by year's end. In the
interim, we investors may have a few months to pick up DNAP shares at (imho)
ridiculously low s/p.
DNAPrint Awarded "High Tech Corridor" Grant
SARASOTA, Fla., Aug 2, 2001 /PRNewswire via COMTEX/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP) announced today that it has been awarded a "High Tech Corridor" grant by the University of South Florida (USF) Office of Economic Development. The grant proposal entitled "A Model System for Cancer Pharmacogenomics" was selected for funding under the USF 2001-2002 External Matching Grant program.
This program awards grants each year to outstanding companies located in the technology corridor of Florida. The aim of the grant program is to apply USF technology and resources for the promotion of economic growth in the state of Florida.
Dr. Hong-Gong Wang from the USF will serve as the principal investigator for the grant and, Hector Gomez, M.D., Ph.D and K. Ponnuswamy, Ph.D. will serve as the leaders for the project on the company side. The grant was written by DNAPrint's Dr. Tony Frudakis. The award provides $305,000 over the next year for the development of an innovative and powerful model system for defining the genetic variance components that underlie variable drug response. The Company intends to use the model system to guide and validate its large-scale population genetics research and product development efforts. If successfully developed and implemented, the model system would impart a significant competitive advantage to DNAPrint within the personalized medicine space.
About the Corridor Program:
The University of South Florida has established one of its mission priorities as promoting regional economic development. "Economic Development," in a higher education setting, signifies links to the public and private sector for the purposes of encouraging high-technology jobs for graduates, helping raise the standard of living through high-technology partnerships, linking with industry to promote funding and real-world applications for USF's research and academic standing, and in general identifying ways that the university can better meet the needs of the private sector and the region in general.
For more information about the Corridor, please visit http://w3.usf.edu./oed
About DNAPrint genomics Inc.:
DNAPrint genomics, Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. The Company has a focused effort within the population genomics, informatics, and clinical fields for the application and production of patient-drug classification tests for personalized medicine. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com.
All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Contacts: For Scientific inquiries:
Tony Frudakis, Ph.D., 941/366-3400
or
Other inquiries
Tim Wilkins, 941/341-0136
http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3Ftextpath%3DCOMTEX%5Cpr%5C2001%5C08%5C02...
Thanks, archangel! Looking for some more pr to come out this month according to the conversation I have with IR last month! Two pr released so far. IR told me that APLOX had merged with a private wireless company and was developing software that would use palm hardware for communications within the mortgage business. He also stated that APLOX was negotiating with a second wireless company. All of this information was prior to the merger pr at the end of July or first of August stating the merger with Mirador was final! The software was in beta testing and should be finished, according to IR this month! We shall see.!!!!
I think 78000 shares or so traded today!!!!!
Happy trading to you too!!!!!! IVRT
MRDR is my pick: Here is the news on it:
Mirador to Acquire Assets of Leading Mortgage Bank Call Center LeadBay.com in Upland, California
VIRGINIA BEACH, Va., Aug 1, 2001 (BUSINESS WIRE) -- Mirador Corporation (OTC: MRDR), announced today it has agreed to acquire the assets, including one of two offices, from a leading mortgage telemarketing firm, LeadBay.com.
Mirador has signed an agreement to purchase the assets of the LeadBay.com office located in Upland, California. The office is a hub of 52 telemarketing personnel with expertise in mortgage lead generation and mortgage loan production. On average, the office currently processes 150 applications per day. Mirador will operate the office as a broker for mortgage loan applications under the Company's trade name HomeSpan.
John Jones, President of Mirador, commented, "LeadBay enjoys tremendous success in the marketplace and is recognized as one the fastest growing call centers in the U.S. Acquiring the LeadBay office should translate to more than one billion dollars of new mortgage loans annually for Mirador. The office also allows Mirador to extend the brand equity of HomeSpan as it will also complement the Company's online presence at HomeSpan.com."
About LeadBay.com
Founded in 1996, Leadbay operates state-of-the-art mortgage banking call centers in Orange and Upland, California. In addition, the Company operates LeadBay.com, an online mortgage banking lead generation search engine. LeadBay.com matches borrowers' finance preferences with mortgage brokers who are pre-screened and have appropriate product offerings to meet borrower requests. LeadBay.com will forward approximately 10,000 quality applications to broker/members each month.
Call Center Solutions, a national publication for the communications industry, named LeadBay.com as one of its "Rising Stars" with a national ranking of 10th in percentage growth for 1999-2000. For additional information, see www.LeadBay.com or call 888-978-9996.
About Mirador Corporation
Mirador Corporation, a financial services provider, operates HomeSpan.com, an Internet portal for consumers and real estate agents. The Company is developing an array of in-demand products and services, including financial planning, insurance product services and investment counseling. These offerings, together with an expanded mortgage-lending service to be operated directly by the Company, will be provided primarily through HomeSpan.com. Mirador also intends to offer telephone and in-person service for its customers that will maintain the highest quality standards of professionalism, product knowledge, responsiveness and courtesy. For additional information, see www.homespan.com and www.otcfn.com/mrdr .
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
CONTACT: OTC Financial Network
Eddie Khoury
781-444-6100 ext. 644
eddie@otcfn.com
URL: http://www.businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2001 Business Wire. All rights reserved.
-0-
KEYWORD: VIRGINIA
INDUSTRY KEYWORD: COMPUTERS/ELECTRONICS
INSURANCE
INTERNET
REAL
ESTATE
MERGERS/ACQ
ADVERTISING/MARKETING
SOURCE:
Mirador
Corporation
News is provided by Financial Insight Systems, Inc.
http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3Ftextpath%3DCOMTEX%5Cbw%5C2001%5C08%5C01...
Mirador to Acquire Assets of Leading Mortgage Bank Call Center LeadBay.com in Upland, California
http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3Ftextpath%3DCOMTEX%5Cbw%5C2001%5C08%5C01...
APLOX merged with Mirador, new symbol on my Etrade accounts now shows MRDR, instead of AXXC! Private wireless company was bought out by APLOX, negotiating with second wireless co now! They intend on using PALM and wireless communications for banks and loan officers to reduce loan application time frames. Got this from IR! IR number is at APLOX web site!
PRS in 3 or 4 weeks, APLOX Investor Relations 1-888-834-6360
Merged with Mirador!!!
Today is officially my last day as investor relations for DNAPrint. Carrie Castillo will be taking over this position full-time starting on Monday July 23rd.
Craig Hall
Article on DNAP & Malaysian biotech:
http://www.newscoast.com/2biz.cfm?ID=49007
Aplox Announces Merger With Mirador
http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3Ftextpath%3DCOMTEX%5Ciw%5C2001%5C07%5C11...
Aplox Enters Into Exclusive Licensing Agreement
INTERNET WIRE -- Aplox Inc. (NQB OTC: AXXC) is pleased to announce it has entered
into an exclusive licensing agreement that will allow Aplox full technology rights to the
BrokerRates Online system. The BrokerRates Online system offers unique/proprietary
web-based applications that can be delivered via a hosted environment or through traditional
license for B2B applications. Aplox applications use Oracle and can offer tailored systems via
the Internet. This exclusive technology utilizes the Internet to its best advantage: moving
information between suppliers and buyers. Aplox will concentrate on applications with symbiotic
relationships among the participants: information suppliers who want to disseminate their
information and buyers who want to access the information wireless.
BrokerRates Online plans to charge $30 for each loan closed through its multi-lender system. In
1999, 8 million residential loans were closed. Of these 8 million loans, 5.6 million were closed
through brokers, which represents a $168 million market annually. The market potential of the
multi-lender site, software licensing, custom applications and other financial applications
represents several billion dollars.
Aplox is additionally in strong pursuit to acquire or form strategic partnerships through licensing
agreements with young emerging companies who hold future technology. It is Aplox's believes
that by building a platform with multiple future technologies it can aggressively leverage its
strength in the market place.
Aplox's target market will be small to mid size lenders who close between $50 million to $15
billion of loans per year. The first priority will be to quickly register enough wholesale lenders to
enable BrokerRates Online to reach a "critical mass" of rate and loan data to appeal to a large
number of brokers. BrokerRates Online expects to reach the critical mass of 5 new lenders in
the first six months. The initial sales and marketing effort will be along the eastern seaboard from
New York to Florida and, as market penetration improves, expand into other major markets as
rapidly as they can be accommodated.
The first application target is the wholesale mortgage industry. BrokerRates Online offers operational software applications that
provide a simple easy to use solution to two of the biggest problems plaguing the wholesale mortgage lending industry today.
The first problem is getting rates and loan products to market every day in a timely, efficient and cost effective manner. The
second problem is to make it easy and simple for the mortgage broker to do business with the wholesale lender.
The wholesale mortgage industry provides APLOX with three revenue streams:
*Multi-lender website linking Wholesale lenders with Brokers. Licensing Private-Label applications to Banks/Lenders and
Third party servicing companies. Hosting Private-Label applications.
Potential customers are the entire community of over 5,000 residential mortgage lenders and 200,000 licensed brokers and
correspondents. Wholesale mortgage lenders represent approximately 1,200 of these 5,000 lenders. Our market is well
defined.
Aploxs' technology has additional opportunity in several other financial industry segments such as automobile leases and loans,
as well as other loan and lease products.
Additional information on Aplox can be found at www.aplox.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements, other than the statements
of historical facts, contained in this release which are not historical facts may be deemed to contain forward-looking statements
with respect to events, the occurrence of which involves risk and uncertainties, including, without limitation, demand and
competition for the Company's products and services, the availability to the Company of adequate financing to support its
anticipated activities, the ability of the Company to generate cash flow from operations and the ability of the Company to
manage its operations.
Contact:
Investor Relations
703-578-1802
Email this story - Most-emailed articles - Most-viewed articles
More Quotes and News:
OTC BB:AXXC.OB - news
AXXC APLOX , INC
Forward event:: Aplox anticipates its first Mortgage Wholesale Bank to sign on with the company in the next 30 days.
Impact date: Within 45 days
Latest news: http://www.aplox.com/
Aplox Technology: http://www.aplox.com/page461677.htm
Blue Chip Technology
Broker Rates Online
BrokerRates Online provides mortgage lending rates online in an easy-to-use format so that mortgage brokers and mortgage lenders can more easily and quickly secure loans for their customers.
With its secret patented software process, BrokerRates has solved two of the biggest problems of the wholesale mortgage lending industry:
? getting mortgage rates and loan products to market every day in a timely, efficient, and
cost effective manner and
? to simplify the process by which lenders, mortgage brokers, and customers secure and
lock mortgages.
Previously, the mortgage industry used facsimiles to transmit mortgage loan rates daily. This cumbersome and antiquated system was inefficient, costly, and stood in start contrast to the high tech revolution affecting the rest of the business world.
Until BrokerRates.
BrokerRates is an innovator. Not satisfied to having brought revolutionary change to the mortgage loan industry, its vision and strategic goal is to have customers lock loans through advanced Wireless Communication systems within three years.
The Company seeks is to be the dominant channel in the US for mortgage loan information and for registering loan agreements between brokers, wholesale mortgage lenders, and their customers.
The BrokerRates Online business-to-business solution is simple, focused and straightforward.
It's either a pp or a requiired r/s by a financial institution whom will require DNAP to be worh X dollars, instead of
x cents worth!!!!! The pp is a given for any small penny stock trying to gain market presence and share! Look at
SSPC, they are increasing their shares to prepare for expansion of a legitimate product. Shareholders are the
ultimate concern of public trading companies, at least they should be! Increasing the equity/assets of a company
is a given for officers of a company as well. They want the BIG BUCKS too! Research and revenues do not grow
on trees. Someone has to "cough up the venture cash!" I cannot see where a few more million shares will hurt DNAP!
The end results will more than off set the dilution; one or two solutions and DNAP will be on it's way, imho!!!!
Take care, IVRT
The Bear Market is Over- The Bull is Back!
Corporate performance has been dismal as the economy continues to wrestle with the
current slow down. One wonders why stocks would begin to come back with no sign of an
economic rebound? The answer is simple and can be found by examining events of the
past year.
Understanding The Past To Predict The Future
One year ago the NASDAQ was testing 3000, down from the high of 5200 in March. This
drop correctly reflected the "irrational exuberance" priced into stock values.
The market retested 4200 twice during the summer of 2000 as stocks trended higher.
The nastiest Bear in the history of NASDAQ sunk its teeth into the wallets of investors
from September of 2000 into early April of 2001 leaving many portfolios decimated.
Stocks prices were destroyed in the 4th quarter of last year, but news of layoffs, earnings
disappointments and lack of visibility did not surface until January. Downgrades were
coming in hordes from Wall Street analysts after stocks had already gotten clobbered.
The market knew the business climate was terrible long before investors heard it from
Wall Street and the financial media.
Stocks are now beginning to trend higher in the absence of corporate performance, which
is puzzling to many investors. We are experiencing the inverse of last year's bear. The
market is a forward looking mechanism, and today's prices are moving based on the
market's perception of where companies will be in six months.
Experienced money managers know the aggressive interest rate cuts from the FED will
eventually lead to an upturn in corporate performance. Excess supplies of technology from
the overfunded tech sector are being absorbed, and once we arrive at increasing
demand for decreasing inventory companies will rebound.
The market won't go straight up. There will be some pullbacks and hiccups along the way.
We have arrived at the point where pullbacks will be met with buyers, and you should now
put your sidelined capital to work. Just as analysts were behind the curve in the Bear
Market, they are behind now. Don't wait for them to come out with buy recommendations
after stocks have already appreciated 40%. The BULL is back, and the next economic
expansion could be the most prolific in history.
The OTCjournal.com
New E-Mail from C Hall 5/21/01 (from tin on rb, Thanks tin for the email)
Larry,
I was contacted by Craig Hjalmarson from http://www.greedorfear.com/ to participate in
this interview. The next several months look to be a very exciting time for DNAPrint and I
encourage current and potential investors to attend.
Knobias completed their video tour last week and DNAPrint should be up on their
website after Knobias has had the opportunity to do the necessary editing (probably
about 3 weeks). You can register for their service at http://www.knobias.com/ .
Regards,
Craig Hall
Investor Relations
Stockholder, I think we can expect a discovery to be made public in the near term. TBFC has stipulated more cash will be made available per benchmarks! The retinome project should garner DNAP more cash!!! The public release of this discovery will probably not move DNAP to much, but it should create greater investor awareness of DNAP's potential! IMHO
Have a good day too!
IVRT
Emory University, NuTec Sciences, IBM Develop Genomics-Based System to Individualize Cancer Treatments
http://news.moneycentral.msn.com/ticker/article.asp?Symbol=US:IBM&Feed=BW&Date=20010503&...
Pops, I could not have said it any better, I second your post!!!!!!!
Missed you in the GL chat room yesterday!!!!!
IVRT
Thanks for the invite! My biotech pick is DNAP! Link to DD is http://www.sockthestocks.com/profiles/dnap.htm
I also like generic drug Co. DYGN!!! It could be the next Barr, Geneva or old Rugby!!!! DYGN DD link is http://ragingbull.lycos.com/mboard/boards.cgi?board=DYGN&read=7093
NEOP and MABA are two other biotech Co that I follow!!!
DNAPrint Announces Another Blood Supply Relationship
http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3Ftextpath%3DCOMTEX%5Cbw%5C2001%5C04%5C12...
Always glad to help my director, pops!!! Hope you are doing well too!
IVRT
jorjenzak, we already knew that some people were "fast acetylators" and others were not! This meant that certain people could metabolize a drug faster than others! Also, the liver helps conjugate certain drugs to make them water soluble. Water solubulizing occurs by two primary paths: glucoronidation or sulfonation! These pathways form water soluble metabolites that can be eliminated by the kidney! The only thing these guys did was to provide a test that helps determine which people metabolize drugs faster than others or conjugate drugs better than other people.
DNAP is going a lot "deeper" than this!!!
IVRT